Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Nephrol. Mar 25, 2026; 15(1): 116620
Published online Mar 25, 2026. doi: 10.5527/wjn.v15.i1.116620
Published online Mar 25, 2026. doi: 10.5527/wjn.v15.i1.116620
Five-year follow-up sustained remission with rituximab in a patient with focal segmental glomerulosclerosis: A case report
Ana Flávia Moura, Daniela Moura-Landim, José A Moura-Neto, Department of Medicine, Bahiana School of Medicine and Public Health, Salvador 40290-000, Bahia, Brazil
Paulo Novis Rocha, Department of Medicine and Diagnostic Support, School of Medicine of Bahia, Federal University of Bahia, Salvador 40110-100, Bahia, Brazil
Jose A Moura Jr, Department of Nephrology, Nephrology and Hypertension Institute, Salvador 40110-100, Bahia, Brazil
Author contributions: Moura AF contributed to data collection, writing - original draft; Rocha PN contributed to data collection critical review of the manuscript; Moura-Landim D contributed to data curation, literature review, manuscript editing; Moura Jr JA contributed to clinical supervision, writing - review and editing; Moura-Neto JA contributed to project administration, patient follow-up, critical revision of the manuscript, final approval; Moura AF and Rocha PN contributed to conceptualization, patient management.
Informed consent statement: Written informed consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: All authors declare that they have no conflict of interest to disclose.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Corresponding author: Ana Flávia Moura, MD, PhD, FASN, Department of Medicine, Bahiana School of Medicine and Public Health, Av D. Joao VI, Salvador 40290-000, Bahia, Brazil.
Received: November 17, 2025
Revised: December 1, 2025
Accepted: December 23, 2025
Published online: March 25, 2026
Processing time: 118 Days and 15.9 Hours
Revised: December 1, 2025
Accepted: December 23, 2025
Published online: March 25, 2026
Processing time: 118 Days and 15.9 Hours
Core Tip
Core Tip: This case report describes a patient with steroid- and calcineurin inhibitor-dependent primary focal segmental glomerulosclerosis (FSGS) who achieved complete and sustained remission for five years following a two-dose regimen of rituximab (RTX). The case highlights the potential of RTX as a steroid- and calcineurin inhibitor-sparing agent in adult FSGS, particularly in patients with significant toxicity or dependence on standard immunosuppressive therapy. The extended follow-up adds valuable insight into the long-term efficacy and safety of RTX in this challenging population.